BCL2/BCL-w/BCL-XL inhibitors are showing promise in haematological malignancies such as chronic lymphocytic leukaemia (CLL), but will require combination to be effective in solid tumours. Here, BCL2L1 is linked to B-cell chronic lymphocytic leukemia.